

September 26, 2025

Dept. of Corporate Services
BSE Ltd.
P J Towers,
Dalal Street,
Mumbai – 400 001.

Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra Kurla Complex
Bandra (East), Mumbai 400051.

BSE Scrip Code: 524735

NSE Symbol: HIKAL

Subject: Hikal's Jigani Unit- US FDA Inspection - Updates.

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Dear Sir / Madam,

This is in continuation to our earlier submission dated August 21, 2025 with regards to Warning Letter received from USFDA. We are submitting the same update as per Regulation 30(13) of SEBI LODR, 2015 read with SEBI Circular dated February 25, 2025, on Industry Standards Forum as per the query received from NSE vide their email dated 24th September, 2025.

I, the undersigned state and declare that the information and details provided in Form A, in compliance with Regulation 30(13) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, is true, correct and complete to the best of my knowledge and belief.

We request you to take the above on record.

Thanking you,
Yours Sincerely,
for HIKAL LIMITED,

Rajasekhar Reddy
Company Secretary and Compliance Officer

Hikal Ltd.

Admin. Office: Great Eastern Chambers, 6th Floor, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India. Tel. + 91-22-6277 0299, + 91-22-6866 0300

Regd. Office: 717, Maker Chambers - 5, Nariman Point, Mumbai - 400 021, India. Tel. +91-22 6277 0477. Fax: + 91-22 6277 0500

www.hikal.com info@hikal.com CIN: L24200MH1988PTC048028

Form-A

Disclosure by Hikal Limited regarding receipt of communication from regulatory, statutory, enforcement or judicial authority under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

[Regulation 30(13) – Disclosure of communication from regulatory, statutory, enforcement or judicial authority]

Sr. No.	Particulars	Details
1	Name of the listed company	Hikal Limited
2	Type of communication received	Warning Letter for Hikal site located at 72-82 A, KIADB Industrial Area, Jigani, Karnataka- 560 105
3	Date of receipt of communication	21 st August, 2025
4	Authority from whom communication received	United States Food and Drug Administration (US FDA)
5	Brief summary of the material contents of the communication received, including reasons for receipt of the communication	Hikal's Bangalore site was inspected by the USFDA from 3 rd February – 7 th February 2025. Six observations in Form 483 were issued at the end of the inspection. Based on the observations, the USFDA classified our site with an "Official Action Intended" status on 21 st May 2025 and further issued a Warning Letter on 21 st August 2025. The USFDA has cited inadequate investigations of customer complaints on foreign matter and shortcomings in our vendor management as the reasons for the issuance of Warning Letter
6	Period for which communication would be applicable, if stated	Communication will be applicable until a reinspection of the facility by the USFDA in due course.
7	Expected financial implications on the listed company, if any	Potential Delay in revenues from first half of the financial year into the second half of the financial year.
8	Details of any aberrations/non-compliances identified by the authority in the communication	The USFDA has identified inadequate investigations of market complaints on foreign matter and gaps in our vendor management program as the main aberrations
9	Details of any penalty or restriction or sanction imposed pursuant to the communication	Nil

Hikal Ltd.

Admin. Office: Great Eastern Chambers, 6th Floor, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India. Tel. + 91-22-6277 0299, + 91-22-6866 0300

Regd. Office: 717, Maker Chambers - 5, Nariman Point, Mumbai - 400 021, India. Tel. +91-22 6277 0477. Fax: + 91-22 6277 0500

www.hikal.com info@hikal.com CIN: L24200MH1988PTC048028

Sr. No.	Particulars	Details
10	Action(s) taken by listed company with respect to the communication	Hikal has responded to the Warning Letter on 11 th September, 2025 with several corrective actions, many of which have already been implemented. Hikal is committed to work closely with US FDA to resolve their concerns
11	Any other relevant information	NA

Hikal Ltd.

Admin. Office: Great Eastern Chambers, 6th Floor, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India. Tel. + 91-22-6277 0299, + 91-22-6866 0300

Regd. Office: 717, Maker Chambers - 5, Nariman Point, Mumbai - 400 021, India. Tel. +91-22 6277 0477. Fax: + 91-22 6277 0500

www.hikal.com info@hikal.com CIN: L24200MH1988PTC048028